NeuralCure AI Partners with Leading Medical Imaging Provider to Enhance AI-Powered Diagnostic Support for Physicians
AI-Driven Insights to Be Integrated with Life Imaging FLA’s Full-Body CT Scan Services Through Their Upcoming 200 Location Expansion DENVER and BOCA RATON, Fla., Feb. 28, 2025 /PRNewswire/ — NeuralCure AI, a breakthrough AI platform transforming diagnostic decision-making, has announced
Canadian Investment Regulatory Organization Trade Resumption – AAV
TORONTO, Feb. 28, 2025 /CNW/ – Trading resumes in: Company: Advantage Energy Ltd. TSX Symbol: AAV All Issues: Yes Resumption (ET): 8:30 AM CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to en
Costa Rica Maintains Strong FDI Momentum: 73 Investment Projects with CINDE’s Strategic Support
Costa Rica’s foreign investment figures for 2024 include 21 new companies, 52 reinvestment projects, and 5,500 new net jobs. Changing technologies, international politics, improved incentives among competitors, and a battle for talent in high-demand areas were some of the challenges facing t
A Night of Elegance and Extravagance: Central Park Estates Curates a Luxurious Sundowner Soirée
Hosted at Bellavista Residences, it was an unparalleled celebration of elegance, exclusivity, and experiential luxury GURUGRAM, India, Feb. 28, 2025 /PRNewswire/ — Central Park Estates, a leading Gurugram-based real estate developer owned by the Bakshi Group of Enterprises, hosted an extraordi
Lilly’s Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with a BTK inhibitor
The positive opinion is based on results from the Phase 3 BRUIN CLL-321 trial, recently presented at the 2024 American Society of Hematology Annual Meeting BRUIN CLL-321 is the first randomized Phase 3 study in CLL ever conducted exclusively in patients previously treated with a BTK inhibitor INDI
Lilly’s Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with a BTK inhibitor
The positive opinion is based on results from the Phase 3 BRUIN CLL-321 trial, recently presented at the 2024 American Society of Hematology Annual Meeting BRUIN CLL-321 is the first randomized Phase 3 study in CLL ever conducted exclusively in patients previously treated with a BTK inhibitor INDI
Canadian Investment Regulatory Organization Trade Resumption – AAV
TORONTO, Feb. 28, 2025 /CNW/ – Trading resumes in: Company: Advantage Energy Ltd. TSX Symbol: AAV All Issues: Yes Resumption (ET): 8:30 AM CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to en
Costa Rica Maintains Strong FDI Momentum: 73 Investment Projects with CINDE’s Strategic Support
Costa Rica’s foreign investment figures for 2024 include 21 new companies, 52 reinvestment projects, and 5,500 new net jobs. Changing technologies, international politics, improved incentives among competitors, and a battle for talent in high-demand areas were some of the challenges facing t
" title="GDETO launches “Hong Kong Mega Events HSR” campaign to promote the city to nine GBA Mainland municipalities
GUANGZHOU, China, Feb. 28, 2025 /PRNewswire/ — Starting from late February, the Hong Kong Economic and Trade Office in Guangdong (GDETO) of the Government of the Hong Kong Special Administrative Region has launched the “Hong Kong Mega Events High Speed Rails” promotion campaign to
GDETO launches “Hong Kong Mega Events HSR” campaign to promote the city to nine GBA Mainland municipalities
GUANGZHOU, China, Feb. 28, 2025 /PRNewswire/ — Starting from late February, the Hong Kong Economic and Trade Office in Guangdong (GDETO) of the Government of the Hong Kong Special Administrative Region has launched the “Hong Kong Mega Events High Speed Rails” promotion campaign to
